3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hematologic Neoplasms
4
Thrombocytopenia
2
Hemorrhage
2
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
44
fludarabine phosphate
39
Peripheral Blood Stem Cell Transplantation
36
Busulfan
33
Antilymphocyte Serum
26
Cyclosporine
25
Tacrolimus
24
Filgrastim
23
Mycophenolic Acid
22
Methotrexate
22
Radiotherapy
21
Melphalan
16
Etoposide
15
Cytarabine
15
Whole-Body Irradiation
14
Methylprednisolone
13
Cord Blood Stem Cell Transplantation
12
Biopsy
8
Azacitidine
8
Sirolimus
7
Flow Cytometry
7
Cyclosporins
7
Alemtuzumab
7
Thiotepa
6
Specimen Handling
6
Psychiatric Rehabilitation
6
Decitabine
6
sargramostim
5
ruxolitinib
5
Rituximab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
Tranexamic Acid
×
Other hematologic neoplasm
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled